GlassScriptPhysician profile
Hely Shah
NPI 1912770660
$1,679.46
in general payments reported to CMS, 2019-2025
32 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $443 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.46 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $111.28 | 2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $110.77 | 2025 | |
| Abbvie INC. | $102.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $96.40 | 2024-2025 | Imfinzi, Lynparza |
| Ipsen Biopharmaceuticals, INC | $96.31 | 2024-2025 | Onivyde |
| Genzyme Corporation | $86.30 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $79.49 | 2024-2025 | Myrisk, Precisetumor |
| Sanofi-Aventis U.S. LLC | $79.00 | 2024 | |
| Merck Sharp & Dohme LLC | $69.88 | 2025 | Keytruda |
| Genentech USA, INC. | $69.78 | 2025 | Itovebi, Tecentriq, Polivy |
| Deciphera Pharmaceuticals INC. | $62.18 | 2025 | Qinlock, Romvimza |
| Array Biopharma INC | $59.64 | 2025 | Lorbrena, Tukysa, Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $54.27 | 2024-2025 | Fruzaqla, Iclusig |
| Celgene Corporation | $48.37 | 2024-2025 | Opdualag, Reblozyl |
| Gilead Sciences, INC. | $47.97 | 2025 | Trodelvy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.83 | 2024-2025 | |
| Astellas Pharma US INC | $43.14 | 2024-2025 | Cresemba, Xtandi |
| Janssen Biotech, INC. | $42.00 | 2025 | Carvykti, Rybrevant |
| Lilly USA, LLC | $40.67 | 2024-2025 | Verzenio, Jaypirca |
| Rigel Pharmaceuticals, INC. | $37.91 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.91 | 2025 | |
| Alexion Pharmaceuticals, INC. | $31.66 | 2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $29.14 | 2025 | Libtayo |
| Taiho Oncology, INC. | $28.83 | 2025 | |
| Novocure INC. | $25.92 | 2025 | Optune Lua (Novottf-200t) |
| Springworks Therapeutics, INC. | $25.71 | 2024 | Ogsiveo |
| Glaxosmithkline, LLC. | $25.05 | 2025 | Jemperli, Zejula |
| Emd Serono, INC. | $22.94 | 2025 | |
| Beone Medicines USA, INC. | $21.53 | 2025 | Brukinsa |
| Fennec Pharmaceuticals, INC. | $19.12 | 2025 | Fyarro |
| Eisai INC. | $17.24 | 2025 | |
| Beigene USA, INC. | $13.62 | 2024 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hely Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.